Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|July 7, 2020

Sorrel to Open a New Manufacturing Facility

The new site will offer initial design and development, low-volume manufacturing, and scalable high-quality production of wearable drug delivery devices.

Sorrel Medical, an Israel-based developer and manufacturer of wearable drug delivery devices, announced on July 7, 2020 that it is opening a new manufacturing facility with cleanroom facilities to further scale its wearable drug delivery devices.

According to a company press release, the new site will offer initial design and development, low-volume manufacturing, and scalable high-quality production of wearable drug delivery devices. With the new 80-m2 cleanroom, the company will be able to increase its production capacity to hundreds of thousands of units per year.

“As Sorrel continues to grow, this new facility will enable us to support global pharmaceutical and biotechnology partners to bring next-generation drug delivery solutions to patients," said Bentsi Algazi, vice president of Operations at Sorrel, in the press release. "These enhanced production scale-up capabilities will enable us to positively impact countless patients living with chronic and high burden conditions."

Source: Sorrel

 

 


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.